Peapod Lane Capital LLC Invests $1.27 Million in Metagenomi, Inc. (NASDAQ:MGX)

Peapod Lane Capital LLC acquired a new stake in Metagenomi, Inc. (NASDAQ:MGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 351,213 shares of the company's stock, valued at approximately $1,268,000. Peapod Lane Capital LLC owned approximately 0.94% of Metagenomi as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MGX. Geode Capital Management LLC grew its holdings in shares of Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company's stock worth $734,000 after purchasing an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Metagenomi by 209.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company's stock worth $296,000 after buying an additional 92,468 shares during the period. Fortitude Advisory Group L.L.C. acquired a new stake in shares of Metagenomi in the 4th quarter valued at $273,000. Spire Wealth Management purchased a new stake in Metagenomi during the 4th quarter worth about $267,000. Finally, Marquette Asset Management LLC acquired a new position in Metagenomi in the fourth quarter valued at approximately $184,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MGX shares. HC Wainwright lifted their target price on Metagenomi from $7.00 to $14.00 and gave the stock a "buy" rating in a research report on Tuesday, December 10th. Chardan Capital reiterated a "buy" rating and issued a $15.00 price objective on shares of Metagenomi in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $16.67.

Metagenomi Trading Up 6.5 %

Shares of NASDAQ MGX traded up $0.16 on Monday, reaching $2.61. 977,060 shares of the company traded hands, compared to its average volume of 1,786,459. Metagenomi, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $12.74. The company has a 50 day moving average of $3.15 and a 200 day moving average of $2.67.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.